JAK2 V617F mutation testing in polycythemia vera: use and impact in an academic practice.

doi:10.1097/MAJ.0b013e3181695687

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

JAK2 V617F mutation testing in polycythemia vera: use and impact in an academic practice.

The American journal of the medical sciences - 1 Oct 2008

Means Robert T

Abstract excerpt

BACKGROUND: The observation that a mutation in JAK2 (JAK2 V617F) is present in more than 90% of cases of polycythemia vera (PV) has altered the diagnostic approach to this disease. However, most studies of the utility of JAK2 V617F have been performed in large PV populations; most hematologists or hematologist-oncologists have relatively few PV patients in their individual practices. APPROACH: To assess its...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Academic Medical Centers
Share to Aged
Share to Aged, 80 and over
Share to JAK2 gene
Share to Genetic Testing
Share to Janus Kinase 2
Share to Mutation
Share to Polycythemia Vera

Source

Open in PubMed

Identifiers

PMID: 18854675
DOI: 10.1097/MAJ.0b013e3181695687

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics